T
Toni K. Choueiri
Researcher at Harvard University
Publications - 1230
Citations - 84800
Toni K. Choueiri is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 107, co-authored 1071 publications receiving 59514 citations. Previous affiliations of Toni K. Choueiri include University of Ulsan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
The Immune Landscape of Cancer
Vesteinn Thorsson,David L Gibbs,Scott D. Brown,Denise M. Wolf,Dante S. Bortone,Tai-Hsien Ou Yang,Eduard Porta-Pardo,Galen F. Gao,Christopher L. Plaisier,James A. Eddy,Elad Ziv,Aedín C. Culhane,Evan O. Paull,I K Ashok Sivakumar,Andrew J. Gentles,Raunaq Malhotra,Farshad Farshidfar,Antonio Colaprico,Joel S. Parker,Lisle E. Mose,Nam S Vo,Jianfang Liu,Yuexin Liu,Janet S. Rader,Varsha Dhankani,Sheila Reynolds,Reanne Bowlby,Andrea Califano,Andrew D. Cherniack,Dimitris Anastassiou,Davide Bedognetti,Arvind Rao,Ken Chen,Alexander Krasnitz,Hai Hu,Tathiane M. Malta,Houtan Noushmehr,Houtan Noushmehr,Chandra Sekhar Pedamallu,Susan Bullman,Akinyemi I. Ojesina,Andrew Lamb,Wanding Zhou,Hui Shen,Toni K. Choueiri,John N. Weinstein,Justin Guinney,Joel H. Saltz,Robert A. Holt,Charles E Rabkin,Alexander J. Lazar +50 more
TL;DR: An extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA identifies six immune subtypes that encompass multiple cancer types and are hypothesized to define immune response patterns impacting prognosis.
Journal ArticleDOI
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
TL;DR: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton,Margaret Morgan,Preethi H. Gunaratne,Preethi H. Gunaratne,David A. Wheeler,Richard A. Gibbs,Gordon Robertson,Andy Chu,Rameen Beroukhim,Kristian Cibulskis,Sabina Signoretti,Fabio Vandin,Hsin-Ta Wu,Benjamin J. Raphael,Roel G.W. Verhaak,Pheroze Tamboli,Wandaliz Torres-Garcia,Rehan Akbani,John N. Weinstein,Victor E. Reuter,James J. Hsieh,A. Rose Brannon,A. Ari Hakimi,Anders Jacobsen,Giovanni Ciriello,Boris Reva,Christopher J. Ricketts,W. Marston Linehan,Joshua M. Stuart,W. Kimryn Rathmell,Shen Hui,Peter W. Laird,Donna M. Muzny,Caleb F. Davis,Xi Liu,Kyle Chang,Nipun Kakkar,Lisa R. Trevino,Susan M. Benton,Jeffrey G. Reid,Donna Morton,Harsha Doddapaneni,Han Yi,Lora Lewis,Dinh Huyen,Christie Kovar,Yiming Zhu,Jireh Santibanez,Wang Min,Walker Hale,Divya Kalra,Gad Getz,Michael S. Lawrence,Carrie Sougnez,Scott L. Carter,Andrey Sivachenko,Lichtenstein Lee,Chip Stewart,Doug Voet,Sheila Fisher,Stacey Gabriel,Eric S. Lander,Steve Schumacher,Barbara Tabak,Gordon Saksena,Robert C. Onofrio,Andrew D. Cherniack,Jeff Gentry,Kristin G. Ardlie,Matthew Meyerson,Hye Jung E. Chun,Andrew J. Mungall,Payal Sipahimalani,Dominik Stoll,Adrian Ally,Miruna Balasundaram,Yaron S.N. Butterfield,Rebecca Carlsen,Candace Carter,Eric Chuah,Robin J.N. Coope,Noreen Dhalla,Sharon M. Gorski,Ranabir Guin,Carrie Hirst,Martin Hirst,Robert A. Holt,Chandra Lebovitz,Darlene Lee,Haiyan I. Li,Michael Mayo,Richard A. Moore,Erin Pleasance,Patrick Plettner,Jacqueline E. Schein,Arash Shafiei,Jared R. Slobodan,Angela Tam,Nina Thiessen,Richard Varhol,Natasja Wye,Yongjun Zhao,Inanc Birol,Steven J.M. Jones,Marco A. Marra,J. Todd Auman,Donghui Tan,Corbin D. Jones,Katherine A. Hoadley,Piotr A. Mieczkowski,Lisle E. Mose,Stuart R. Jefferys,Michael D. Topal,Christina Liquori,Yidi J. Turman,Shi Yan,Scot Waring,Elizabeth Buda,Jesse Walsh,Junyuan Wu,Tom Bodenheimer,Alan P. Hoyle,Janae V. Simons,Mathew G. Soloway,Saianand Balu,Joel S. Parker,D. Neil Hayes,Charles M. Perou,Raju Kucherlapati,Peter J. Park,Timothy J. Triche,Daniel J. Weisenberger,Phillip H. Lai,Moiz S. Bootwalla,Dennis T. Maglinte,Swapna Mahurkar,Benjamin P. Berman,David Van Den Berg,Leslie Cope,Stephen B. Baylin,Michael S. Noble,Daniel DiCara,Hailei Zhang,Juok Cho,David I. Heiman,Nils Gehlenborg,William Mallard,Lin Pei,Scott Frazer,Petar Stojanov,Yingchun Liu,Lihua Zhou,Jaegil Kim,Lynda Chin,Lynda Chin,Christopher C. Benz,Christina Yau,Sheila Reynolds,Ilya Shmulevich,Rahul Vegesna,Hoon Kim,Zhang Wei,David Cogdell,Eric Jonasch,Zhiyong Ding,Yiling Lu,Nianxiang Zhang,Anna K. Unruh,Tod D. Casasent,Chris Wakefield,Dimitra Tsavachidou,Gordon B. Mills,Jianjiong Gao,Ethan Cerami,Benjamin Gross,B. Arman Aksoy,Rileen Sinha,Nils Weinhold,S. Onur Sumer,Barry S. Taylor,Ronglai Shen,Irina Ostrovnaya,Michael F. Berger,Marc Ladanyi,Chris Sander,Suzanne S. Fei,Andrew J. Stout,Paul T. Spellman,Daniel L. Rubin,Tiffany Ting Liu,Ng Sam,Evan O. Paull,Daniel E. Carlin,Theodore C. Goldstein,Peter Waltman,Kyle Ellrott,Zhu Jing,David Haussler,Weimin Xiao,Candace Shelton,Johanna Gardner,Robert Penny,Mark E. Sherman,David Mallery,Scott Morris,Joseph Paulauskis,Ken Burnett,Troy Shelton,William G. Kaelin,William G. Kaelin,Toni K. Choueiri,Michael B. Atkins,Erin Curley,Satish K. Tickoo,Leigh B. Thorne,Lori Boice,Huang Mei,Jennifer C. Fisher,Cathy D. Vocke,James Peterson,Robert Worrell,Maria J. Merino,Laura S. Schmidt,Laura S. Schmidt,Bogdan Czerniak,Kenneth Aldape,Christopher G. Wood,Jeff Boyd,Jo Ellen Weaver,Mary Iacocca,Nicholas J. Petrelli,Gary Witkin,Jennifer Brown,Christine Czerwinski,Lori Huelsenbeck-Dill,Brenda Rabeno,Jerome Myers,Carl Morrison,Julie Bergsten,John Eckman,Jodi Harr,Christine I. Smith,Kelinda Tucker,Leigh Anne Zach,Wiam Bshara,Carmelo Gaudioso,Rajiv Dhir,Jodi K. Maranchie,Joel B. Nelson,Anil V. Parwani,Cureline Olga Potapova,Konstantin V. Fedosenko,John C. Cheville,R. Houston Thompson,Juan M. Mosquera,Mark A. Rubin,Michael L. Blute,Todd Pihl,Mark A. Jensen,Robert Sfeir,Ari B. Kahn,Anna Chu,Prachi Kothiyal,Eric E. Snyder,Joan Pontius,Brenda Ayala,Mark Backus,Jessica Walton,Julien Baboud,Dominique L. Berton,Matthew C. Nicholls,Deepak Srinivasan,Rohini Raman,Stanley Girshik,Peter A. Kigonya,Shelley Alonso,Rashmi N. Sanbhadti,Sean P. Barletta,David Pot,Margi Sheth,John A. Demchok,Tanja Davidsen,Zhining Wang,Liming Yang,Roy Tarnuzzer,Jiashan Zhang,Greg Eley,Martin L. Ferguson,Kenna R. Mills Shaw,Mark S. Guyer,Bradley A. Ozenberger,Heidi J. Sofia +291 more
TL;DR: Remodelling cellular metabolism constitutes a recurrent pattern in ccRCC that correlates with tumour stage and severity and offers new views on the opportunities for disease treatment.
Journal ArticleDOI
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt,Ronald de Wit,David J. Vaughn,Yves Fradet,Jae-Lyun Lee,Lawrence Fong,Nicholas J. Vogelzang,Miguel Angel Climent,Daniel P. Petrylak,Toni K. Choueiri,Andrea Necchi,Winald R. Gerritsen,Howard Gurney,David I. Quinn,Stéphane Culine,Cora N. Sternberg,Yabing Mai,Christian Heinrich Poehlein,Rodolfo F. Perini,Dean F. Bajorin +19 more
TL;DR: Pembrolizumab was associated with significantly longer overall survival and with a lower rate of treatment‐related adverse events than chemotherapy as second‐line therapy for platinum‐refractory advanced urothelial carcinoma.